Next 10 |
2023-11-17 06:28:55 ET More on Athersys Athersys crashes after bankruptcy warning Seeking Alpha’s Quant Rating on Athersys Historical earnings data for Athersys Financial information for Athersys For further details see: Athersys GAAP EPS o...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
2023-11-09 18:00:54 ET More on Athersys Athersys crashes after bankruptcy warning Athersys shares slide on pricing $3.5 million stock offering Seeking Alpha’s Quant Rating on Athersys Historical earnings data for Athersys Financial information ...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...
2023-10-11 07:23:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a hot topic on Wednesday morning and we’re covering all of the latest news investors need to know about! Moving stocks this morning are study results, ban...
2023-10-10 12:13:05 ET Nano-cap biotech Athersys ( NASDAQ: ATHX ) fell ~50% on Tuesday after the developer of MultiStem cell therapy warned about a potential bankruptcy filing following a setback in a Phase 3 trial for the candidate. Cleveland, Ohio-based Athersys ( ATHX ...
The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces that the independent data safe...
Athersys, Inc. (Nasdaq: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC ® ) technology for equine, canine, and feline health applications, announces the s...
2023-10-02 17:17:30 ET More on Athersys Athersys shares slide on pricing $3.5 million stock offering Seeking Alpha’s Quant Rating on Athersys Historical earnings data for Athersys Financial information for Athersys For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million pri...